Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

737
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
737
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.5K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanosensitive TRPV4 immunohistochemistry improves deep learning-based classification of ductal carcinoma in situ beyond H&E morphology.

The journal of pathology. Clinical research·2026
Same author

Burnout Risk Among Providers of an Integrated Care Program Supporting Transitions Between the Hospital and Home: A Descriptive Mixed Methods Evaluation.

International journal of environmental research and public health·2026
Same author

Non-functioning adrenocortical carcinoma presenting as acute spontaneous retroperitoneal haemorrhage.

Endocrinology, diabetes & metabolism case reports·2026
Same author

A Prospective, Multicenter, Open-Label Assessment of Efficacy and Safety of the Quanta Dialysis System for Home Hemodialysis.

Kidney medicine·2026
Same author

Transamniotic Fetal Delivery of Cystic Fibrosis (CF) Transmembrane Conductance Regulator (CFTR) mRNA.

FASEB bioAdvances·2026
Same author

Esophagus engineering tackles function.

Nature biotechnology·2026

Related Experiment Video

Updated: Dec 25, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.6K

Hematogenous Donor Cell Routing Pathway After Transamniotic Stem Cell Therapy.

Sarah A Tracy1, Alexander V Chalphin1, Ina Kycia1

  • 1Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Stem Cells and Development
|April 2, 2020
PubMed
Summary

Donor mesenchymal stem cells (MSCs) injected into amniotic fluid follow a controlled pathway to the placenta. This transgestational membrane transport route opens new possibilities for stem cell therapies.

Keywords:
TRASCETamniotic mesenchymal stem cellfetal cell therapyfetal stem celltransamniotic stem cell therapy

More Related Videos

Application of Aorta-gonad-mesonephros Explant Culture System in Developmental Hematopoiesis
07:38

Application of Aorta-gonad-mesonephros Explant Culture System in Developmental Hematopoiesis

Published on: November 3, 2017

8.8K
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

790

Related Experiment Videos

Last Updated: Dec 25, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.6K
Application of Aorta-gonad-mesonephros Explant Culture System in Developmental Hematopoiesis
07:38

Application of Aorta-gonad-mesonephros Explant Culture System in Developmental Hematopoiesis

Published on: November 3, 2017

8.8K
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

790

Area of Science:

  • Regenerative Medicine
  • Developmental Biology
  • Cell Biology

Background:

  • Mesenchymal stem cells (MSCs) administered via intra-amniotic injection have shown therapeutic potential.
  • The kinetic route and transport pathway of these donor MSCs remain incompletely understood.

Purpose of the Study:

  • To elucidate the transport pathway of donor MSCs following intra-amniotic injection.
  • To investigate the cell kinetic route from the amniotic sac to fetal circulation.

Main Methods:

  • In vivo study using luciferase-labeled syngeneic amniotic fluid-derived MSCs (afMSCs) injected into rat fetuses at gestational day 17 (E17).
  • Samples from placenta, chorion, amnion, amniotic fluid, stomach fluid, peripheral blood, and umbilical cord were analyzed daily until term (E18-22) using luminometry.
  • In vitro transwell assays assessed MSC migration through gestational membranes (chorion/amnion).

Main Results:

  • Luciferase activity, indicating MSC presence, was detected in the amnion, chorion, and placenta of fetuses receiving cells, but not in controls.
  • A nonlinear, age-dependent bimodal pattern of luciferase activity was observed in the amnion, chorion, and placenta, peaking at E18 and E22.
  • In vitro, MSCs migrated through gestational membranes, with 39.6% of assays showing cell presence.

Conclusions:

  • Donor MSCs injected intra-amniotically undergo controlled cell routing, not passive clearance.
  • Transgestational membrane transport is the likely pathway for donor MSCs to reach the placenta.
  • This finding significantly expands the potential applications of transamniotic stem cell therapy.